Towards a unique and transmissible vaccine against myxomatosis and rabbit haemorrhagic disease for rabbit populations
Towards a unique and transmissible vaccine against myxomatosis and rabbit haemorrhagic disease for rabbit populations
复制标题
DOI：
10.1071/wr06160
复制
发表时间：
2007-01-01
影响因子：
1.9
通讯作者：
Barcena, Juan
中科院分区：
文献类型：
--
作者：
Angulo, Elena;Barcena, Juan
目前可用的针对粘液瘤病和兔出血性疾病病毒（RHDV）的疫苗不适合对野兔群体进行免疫，因为疫苗需要通过传统兽医实践单独提供。作为一种替代办法，西班牙的研究侧重于研制一种传染性疫苗。以自然减毒的黏液瘤病毒（MV）野毒株为基础，构建了表达rhdv衣壳蛋白（VP60）的重组病毒。在兔接种后，重组病毒（MV- vp60）诱导了针对MV和RHDV的特异性抗体反应，赋予了对这两种病毒致命攻击的保护。此外，重组MV-VP60病毒显示出有限的水平传播能力，无论是通过直接接触还是通过跳蚤介导的过程，促进了接触未接种动物的免疫。已在实验室条件下和有限的实地试验中对疫苗的效力和安全性进行了广泛评价。本综述介绍了传染性疫苗战略的发展以及为获得该疫苗在欧盟的上市许可所采取的步骤。
Currently available vaccines against myxomatosis and rabbit hemorrhagic disease virus (RHDV) are not suited to immunise wild rabbit populations, as vaccines need to be delivered individually by conventional veterinary practices. As an alternative approach, research in Spain has focused on the development of a transmissible vaccine. A recombinant virus has been constructed based on a naturally attenuated myxoma virus (MV) field strain, expressing the R H DV capsid protein (VP60). Following inoculation of rabbits, the recombinant virus (MV-VP60) induced specific antibody responses against MV and RHDV, conferring protection against lethal challenges with both viruses. Furthermore, the recombinant MV-VP60 virus showed a limited horizontal transmission capacity, either by direct contact or in a fleamediated process, promoting immunisation of contact uninoculated animals. Efficacy and safety of the vaccine have been extensively evaluated under laboratory conditions and in a limited field trial. The development of the transmissible vaccine strategy and the steps being taken to obtain the marketing authorisation for the vaccine in the European Union are presented in this review.